Delaying treatment in patients with subfoveal neovascular age-related macular degeneration (wet AMD) correlates to progressive and substantial loss of visual acuity (VA), according to a report published online ahead of print by Eye.
Delaying treatment in patients with subfoveal neovascular age-related macular degeneration (wet AMD) correlates to progressive and substantial loss of visual acuity (VA), according to a report published online ahead of print by Eye.
Luis Arias, MD of Bellvitge University Hospital, Barcelona, Spain and colleagues conducted a retrospective, multicentre, epidemiological study of patients referred to retina specialists following a diagnosis of wet AMD.
The researchers found that the median time period elapsing between diagnosis and the first treatment visit was 2.3 months, and the percentage of patients with a VA of 20/400 or worse doubled from diagnosis (12.4%) to initial treatment visit (24.7%). Length of time between diagnosis and treatment showed a high statistically significant correlation to VA degeneration.
The team concluded that substantial VA loss results from untreated wet AMD.
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.